Cost-effectiveness analysis reveals increased survival and quality-adjusted life years with first-line NALIRIFOX in metastatic pancreatic cancer, suggesting a viable therapeutic alternative.
OBJECTIVE: To evaluate the cost-effectiveness of liposomal Irinotecan (Onivyde) in combination with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) compared to gemcitabine plus nab-paclitaxel (GemNabPac), for the first-line treatment (FLT) of adult patients with metastatic adenocarcinoma of the pancreas (mPDAC) in Greece. METHODS: A partitioned survival model was adapted from a Greek payer perspective over a lifetime horizon. GemNabPac was selected as the comparator, representing the current standard of care in Greece. Clinical efficacy, safety, and utilities were derived from the NAPOLI-3 trial and published literature. Direct medical costs reflecting the year 2026 were included in the analysis. Model outcomes included quality-adjusted life years (QALYs), life years (LYs), total costs, and incremental cost-effectiveness ratios (ICERs). RESULTS: The analysis showed that NALIRIFOX was associated with incremental gains of 0.14 QALYs and 0.16 LYs compared with GemNabPac, at an additional cost of €8,571. The resulting ICERs were €62,810 per QALY gained and €54,326 per LY gained. CONCLUSION: The present study indicates that NALIRIFOX provides clinically meaningful benefits and may represent a cost-effective option for patients with mPDAC in Greece, a population with very limited FLT options, under the assumptions and threshold used.
No takes yet. Share an insight, caveat, or question.
Gourzoulidis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: